Literature DB >> 31267523

Assessment tool for visual perception deficits in cerebral visual impairment: reliability and validity.

Kathleen Vancleef1,2,3, Eva Janssens2,4, Yasmine Petré2, Johan Wagemans2,3, Els Ortibus4,5.   

Abstract

AIM: To evaluate the reliability and validity of the Children's Visual Impairment Test for 3- to 6-year-olds (CVIT 3-6).
METHOD: Reliability was assessed via test-retest correlation and intraclass correlation coefficient (ICC) in typically developing children, children with cerebral visual impairment (CVI), intellectual impairment, and simulated impaired vision (validation groups n=59, mean developmental age=4y 10mo, 27 females, 32 males). Internal validity was evaluated with a confirmatory factor analysis on the normative sample (n=301, median age=4y 8mo, SD=9.7mo, 148 females, 153 males). External validity was assessed by correlating performance on CVIT 3-6 with L94, the Beery-Buktenica Developmental Test of Visuo-Motor Integration (Beery-VMI), the Freiburg Vision Test, the revised Snijders-Oomen Nonverbal Intelligence Test for children between 2 years 6 months and 7-years-old (SON-R 2.5-7), and the Social Responsiveness Scale (SRS) questionnaire and by comparing performance between validation groups.
RESULTS: We observed very good test-retest reliability (r=0.82, p<0.001, ICC=0.80) and confirmed the hypothesized factor structure (comparative fit index=1; Tucker-Lewis index=1.045). We found high correlations with tests with a strong visual perception component (L94: r=0.74, p<0.001; SON-R 2.5-7: r=0.37, p=0.01) and low correlations with other tests (Beery-VMI: r=0.25, p=0.09; SRS: r=0-0.26, p=0.09). Lowest scores were observed for children with CVI compared to the other validation groups (F[3,44]=5.1, p=0.003).
INTERPRETATION: CVIT 3-6 is grounded in knowledge of visual perception. The tool specifically measures CVI-related visual perception deficits and is not mediated by intellectual abilities or low visual acuity. WHAT THE PAPER ADDS: Evidence for good test-retest reliability of the Children's Visual Impairment Test for 3- to 6-year-olds (CVIT 3-6). Factor structure of normative data reflects CVIT 3-6's foundations in vision science. CVIT 3-6 specifically measures visual perception impairments. CVIT 3-6 performance is not influenced by intelligence or low visual acuity.
© 2019 Mac Keith Press.

Entities:  

Mesh:

Year:  2019        PMID: 31267523     DOI: 10.1111/dmcn.14304

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  5 in total

1.  The Multidisciplinary Guidelines for Diagnosis and Referral in Cerebral Visual Impairment.

Authors:  Frouke N Boonstra; Daniëlle G M Bosch; Christiaan J A Geldof; Catharina Stellingwerf; Giorgio Porro
Journal:  Front Hum Neurosci       Date:  2022-06-30       Impact factor: 3.473

2.  Visual Function and Neuropsychological Profile in Children with Cerebral Visual Impairment.

Authors:  Federica Morelli; Giorgia Aprile; Chiara Martolini; Elena Ballante; Lucrezia Olivier; Elisa Ercolino; Eleonora Perotto; Sabrina Signorini
Journal:  Children (Basel)       Date:  2022-06-19

Review 3.  Clinical assessment, investigation, diagnosis and initial management of cerebral visual impairment: a consensus practice guide.

Authors:  Rachel Fiona Pilling; Louise Allen; Richard Bowman; John Ravenscroft; Kathryn J Saunders; Cathy Williams
Journal:  Eye (Lond)       Date:  2022-10-18       Impact factor: 4.456

Review 4.  What assessments are currently used to investigate and diagnose cerebral visual impairment (CVI) in children? A systematic review.

Authors:  Emma L McConnell; Kathryn J Saunders; Julie-Anne Little
Journal:  Ophthalmic Physiol Opt       Date:  2020-12-27       Impact factor: 3.117

5.  Development of the Parental Questionnaire for Cerebral Visual Impairment in Children Younger than 72 Months.

Authors:  Jin Hwa Moon; Gun Ha Kim; Sung Koo Kim; Seunghyo Kim; Young Hoon Kim; JoonSik Kim; Jin Kyung Kim; Byoungho H Noh; Jung Hye Byeon; Jung Sook Yeom; Baik Lin Eun; So Hee Eun; Jieun Choi; Hee Jung Chung
Journal:  J Clin Neurol       Date:  2021-07       Impact factor: 3.077

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.